In this episode, Global Trac Solution’s CEO, David Flores, sits down with Dr. Hyder A. Khoja to learn more about the work they’re doing at Transcendent Therapeutics Inc.
Similar Posts
Wesana Health’s Dr. ABID NAZEER – The Parallels Between Brain Injury & Addiction (WESA)
Wesana Health’s Dr. ABID NAZEER – The Parallels Between Brain…
BIG Updates On MindMed, Compass, NUMI, TRYP, TRUFF, LOBE & More Plus Clinical Trial Progress
Hey psychedelic investors, this week we have Big Updates on MindMed, Compass, NUMI TRYP, TRUFF, ATAI, SHRM and LOBE Sciences and some amazing Ayahuasca study results which are detrimental to DMT research and this molecule potential effects on depression and anxiety.
Timestamps:
0:00 – Intro
0:52- Effects of DMT, taken using the ayahuasca drink, on depression and anxiety
5:26 – MindMed ( MMED / MNMD / MMQ ) stared trading on NASDAQ
6:01 – MindMed finishes phase2a trials for Project LUCY
8:15 – Atai Life Sciences To IPO soon on the Nasdaq and plans to raise $100 million
9:17 – Compass Pathways ( CMPS) to raise $144 million dollars
10:35 – Numinus Wellness ( NUMI ) to begin phase 1 trial for naturally extracted psilocybin in their lab
12:15 TRYP Therapeutics (TRYP) to begin 2 phase 2a trials in 2021
13:50 – Champignon Brands (SHRM) to restart trading in Canada
14:31 – Lobe Sciences (LOBE) & Core one Labs ( CLABF) to create a Joint Venture
15:34 – Red Light Holland (TRUFF) has increased its points of sale by 144% and TRUFF and Halo Collective create Red Light Oregn, INC
Link to Numinus (NUMI) press release: https://www.newswire.ca/news-releases/numinus-announces-phase-1-clinical-trial-of-natural-psilocybin-mushroom-extraction-prepared-at-company-lab-879795202.html?fbclid=IwAR1SmpbsTmXLs-mEy3vsUtAGKKk_xpf3FxJB3n2C-55zGJjiF0naXRetoUs
Link to Compass Pathways (CMPS) : https://www.globenewswire.com/news-release/2021/04/27/2218191/0/en/COMPASS-Pathways-launches-proposed-public-offering.html https://ir.compasspathways.com/static-files/fe6cc477-a2ee-4b4a-bd46-8f8df0b62f30
Link To Atai life Sciences: https://www.atai.life/
Link To MindMed (MMED / MNMD / MMQ) https://mindmed.co/
Link to MindMed clinical trial: https://clinicaltrials.gov/ct2/show/NCT03153579?term=lsd+anxiety&draw=2&rank=1
Link to Red LIght Holland (TRUFF) : https://www.newsfilecorp.com/release/81879/Red-Light-Holland-and-Halo-Collective-Create-Red-Light-Oregon-Inc.-Forwarding-Intentions-to-Enter-Oregon-Medicinal-Psychedelic-Market
https://www.cnbc.com/2021/04/21/atai-ipo-peter-thiel-backed-psychedelics-firm-to-raise-100-million.html
Link to Champignon Brands (SHRM) : https://www.prnewswire.com/news-releases/champignon-brands-announces-revocation-of-cease-trade-orders-301275526.html
Link to DMT study: https://www.sciencedirect.com/science/article/pii/S2666915321000251?fbclid=IwAR1-0HC9fxkL2Z47TEubMGsrqKInj61xLvBK4OW_C3FEQgv5VomoCSoNeQo
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #numiStock
LATEST MindMed News [What Does This Mean For the FUTURE of MMEDF?]
Hey Psychedelic Investors, today we are actually going to have two episodes, one to present the news updates, and then a second one, which will take place in the Speculation Zone to discuss why these may be super important
So make sure you stick around for both.
Timecodes:
0:00 – Intro
3:30 – New Phase 1 Clinical Trial
9:45 – Changes in Leadership
13:19 – New MindMed Partnership
20:30 – Conclusion
So what is the latest MindMed news and what does it mean for the future of MMED/MMEDF?
First up, we have news from the end of January that MindMed has started their phase one clinical trial combining MDMA with LSD.
Why combine these two substances?
What diseases could it help alleviate?
And what is the timeline for this project?
Next we will cover MindMed’s change in leadership structure. A CEO has stepped down, does this mean we are seeing a game of thrones in the boardroom? Well… no. It’s actually much more practical than that.
Here we will cover: Why did they do this, and how will it affect MMED/MMEDF going forward, specifically with MindMed ‘s Nasdaq Uplisting application.
Finally, and most importantly, we will talk about how MindMed is further expanding their development pipeline and IP portfolio through a partnership with a Swiss company called MindShift Compounds. This is very exciting as it ads to MindMed’s ever expanding clinical trial pipeline.
Pretty soon it’s going to be hard keeping track of all of MindMed’s projects.
Hey there guys so before we begin the episode I just want to let you know that I was just interviewed on the channel The Medicine of being Human.
We talked about all sorts of interesting topics and I had a great time.
I am not sure if by the time this video is released, if the interview will already be out, but ill put a link in the description to the Channel, and also to Sena’s Instagram page.
https://www.youtube.com/channel/UChW422KBFaEfB9DJG_cKySQ
https://www.instagram.com/sena__maria/
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video from Pexels
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMEDF #MindmedStock
PSYCHEDELICS & The Mental Health Crisis In America: Anxiety, Depression And Addiction ALL TIME HIGHS
The mental healthcare crisis is escalating: Are Psychedelic Medicines the Solution? Can psychedelics health North America fight against anxiety, depression and addiction?
It is well known that during these unprecedented times of lockdowns and fear, our society’s mental health has taken a toll. Unfortunately, few realize how dire the situation has become.
In some respects, this pandemic has accelerated other health care crises: such as the addiction and overdose crisis, the depression crisis, and the anxiety crisis.
These crises can be hard to see when the illnesses are often hidden by those that are experiencing them, out of shame.
However, we can’t start talking about solutions to the problem until we see how big the problem is.
Therefore, in this episode, we are going to take a look at:
1. Some of the data regarding addiction, depression, and anxiety levels during the pandemic, and show you how stark this increase has been;
2. We will discuss a novel solution which has a lot of evidence backing it up: using psychedelics like magic mushrooms and LSD to treat these maladies of the mind;
Enjoy the episode!
Timestamps:
0:00 – Intro
1:37 – Increased rates of Anxiety, Depression & Addiction in North America
6:24 – Psychedelic inspired medicines – potential solutions?
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Links:
Rates of addiction since the epidemic began:
https://www.kten.com/story/44309290/continued-increase-in-substance-abuse-after-pandemic
Rates of overdose:
https://www.google.com/url?q=https://www.forbes.com/sites/niallmccarthy/2021/07/16/us-experiences-a-historic-spike-in-overdose-deaths-infographic/?sh5452ed443650&sa=D&source=editors&ust=1626828792173000&usg=AOvVaw3NuNLOX7F8X_pg9Uh0Rnhv
Rates of depression:
https://www.meetfieldtrip.com/news/news-details/2021/More-than-80-of-Americans-report-one-or-more-symptoms-of-depression-and-many-have-turned-to-substances-to-cope-with-negative-emotions-during-COVID-19-Pandemic-according-to-Field-Trip-Healths-First-Annual-State-of-Mind-Survey/default.aspx
https://www.nature.com/articles/d41586-021-00175-z
Research into psychedelics as potential alternative treatments
Psilocybin: A potential treatment for depression:
https://newatlas.com/health-wellbeing/psilocybin-therapy-major-depression-trial-results-johns-hopkins/
https://www.imperial.ac.uk/news/219413/magic-mushroom-compound-performs-well-antidepressant/
Psilocybin : A potential cure for Smoking:
https://pubmed.ncbi.nlm.nih.gov/27441452/
Ibogaine: A potential cure for addiction:
https://www.tandfonline.com/doi/full/10.1080/00952990.2017.1310218
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#ANXIETY#DEPRESSION #PsychedelicTherapy
Removing Barriers of Accessibility to Psychedelics with Brett Waters
Brett also introduces the collaborative efforts of Reason for Hope’s team, which includes strategic minds from various fields, working together in drafting legislation, preparing legal briefings, educating legislators, and building advocacy coalitions. Currently, Reason for Hope focuses on establishing MDMA- and psilocybin-assisted therapy expanded access pilot programs for those unable to wait for FDA approval.
Breaking News: MindMed launches LSD Microdosing Trial Treating ADHD (Plus MNMD Stock Discussion)
MindMed (Nasdaq:MNMD, NEO:MMED) has launched recruitment for their phase 2a clinical trial, testing using LSD microdoses to treat Adult ADHD!
MindMed’s stock has been down a lot recently, which has people asking “should I sell MindMed”, or “Is MindMed stock a good investment?”, or “why is MindMed stock down?”.
A lot of this drop has to do with a lack of news, not bad news. Now, at long last we finally have some good news! I have been looking forward to this trial starting for over a year now!
This LSD microdosing study is part of Project Flow, MindMed’s LSD microdosing division.
Microdosing LSD, anecdotally, has been shown to: increase focus; decrease anxiety; increase creativity; and improve mood. As improving focus and decreasing anxiety are two issues individuals with ADHD often need help with, it is possible that this may be a better medication than stimulants like Adderall.
The 52 person, placebo controlled study will give 20 micrograms of LSD to Adult ADHD sufferers twice a week for 6 weeks. Six weeks after treatment, the patients symptoms will be compared to where they were before the trial, and compared against the placebo group.
If they do show significant improvement, it will be the first scientific evidence that LSD microdoses can help treat adult ADHD.
Not only would this help tens of millions of people, it would also be lucrative for MindMed, as in the USA alone, the ADHD treatment market is valued at $12.9 billion annually.
Is LSD microdosing good for you? Can LSD Microdosing improve your mental health and Creativity? MindMed aims to find out!
References:
Press Release
https://www.prnewswire.com/news-releases/mindmed-initiates-phase-2a-lsd-trial-for-the-treatment-of-adult-adhd-301447252.html
MindMed Investor’s Deck
https://mindmed.co/wp-content/uploads/2021/12/MindMed-Presentation-December-2021.pdf
New CEO
https://www.newswire.ca/news-releases/mindmed-appoints-robert-barrow-as-chief-executive-officer-and-director-879570624.html
Microdosing study 1
https://pubmed.ncbi.nlm.nih.gov/34795334/
Microdosing study 2
https://www.theguardian.com/science/2021/mar/02/microdosing-lsd-benefits-might-be-placebo-effect-study-finds
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
@Psychedelic Spotlight
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #Microdosing #ADHD